Harpoon Therapeutics Announces Leadership Change
April 07, 2022 16:05 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference
April 07, 2022 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 10, 2022 16:04 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported...
Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer
March 07, 2022 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217
March 02, 2022 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference
February 09, 2022 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics Provides Pipeline Development Milestones for 2022
January 11, 2022 08:00 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a...
Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021
December 07, 2021 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics Presents Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer
November 12, 2021 07:00 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a...
Harpoon Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 10, 2021 16:05 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...